Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel B Walter

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|November 9, 2021
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of AgeEmmanuel B Walter, Kawsar R Talaat, Charu Sabharwal, et al.
Epidemics|January 17, 2026
Estimating influenza transmission parameters: Comparing two study designs, 2023-2024Jessica E Biddle, Stacey House, Jennie H Kwon, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2020
SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) StudyJillian H Hurst, Sarah M Heston, Hailey N Chambers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2020
Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) StudyJillian H Hurst, Sarah M Heston, Hailey N Chambers, et al.
Nature Communications|November 30, 2023
Engineered immunogens to elicit antibodies against conserved coronavirus epitopesA Brenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus EpitopesBrenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
The New England Journal of Medicine|February 15, 2023
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of AgeFlor M Muñoz, Lawrence D Sher, Charu Sabharwal, et al.
Plos One|November 1, 2011
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccinationM Anthony Moody, Ruijun Zhang, Emmanuel B Walter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|November 9, 2021
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of AgeEmmanuel B Walter, Kawsar R Talaat, Charu Sabharwal, et al.
Epidemics|January 17, 2026
Estimating influenza transmission parameters: Comparing two study designs, 2023-2024Jessica E Biddle, Stacey House, Jennie H Kwon, et al.
Medrxiv : the Preprint Server for Health Sciences|September 10, 2020
SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) StudyJillian H Hurst, Sarah M Heston, Hailey N Chambers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 3, 2020
Severe Acute Respiratory Syndrome Coronavirus 2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) StudyJillian H Hurst, Sarah M Heston, Hailey N Chambers, et al.
Nature Communications|November 30, 2023
Engineered immunogens to elicit antibodies against conserved coronavirus epitopesA Brenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus EpitopesBrenda Kapingidza, Daniel J Marston, Caitlin Harris, et al.
The New England Journal of Medicine|February 15, 2023
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of AgeFlor M Muñoz, Lawrence D Sher, Charu Sabharwal, et al.
Plos One|November 1, 2011
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccinationM Anthony Moody, Ruijun Zhang, Emmanuel B Walter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2023
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical TrialAngela R Branche, Nadine G Rouphael, Cecilia Losada, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Pageof 14